Premix for preventing and treating chicken proventriculitis as well as preparation method and application thereof

Abstract

The invention provides a premix for preventing and treating chicken proventriculitis as well as a preparation method and application thereof, and relates to the technical field of animal feeds. Specifically, the premix comprises a compound probiotic microcapsule, a compound enzyme preparation, a functional auxiliary material and a carrier, the functional auxiliary materials comprise nano modified aluminosilicate, jerusalem artichoke powder, curcumin microcapsules and vitamin E succinate; the composite probiotic microcapsule is prepared by drying a W / O / W emulsion, and an inner-layer water phase of the W / O / W emulsion comprises a probiotic complexing agent. Based on the synergistic effect of bacteria and enzymes, prevention and treatment of chicken proventriculitis are achieved through a multi-target intervention strategy system, and through a triple synergistic mechanism of toxin biodegradation-pathogenic bacteria inhibition-mucosal barrier repair, the proventriculitis is prepared through a three-section micro-capsule embedding technology and a low-temperature solid-state activation technology in the preparation method and a material modification and preparation engineering technology. The problem of component compatibility is innovatively solved, and the efficient, safe and economical premix for preventing and treating proventriculitis is provided.

Description

Technical Field

[0001] The present invention relates to the technical field of animal feeds, and in particular, to a premix for preventing and treating chicken adenogastritis, a preparation method thereof, and an application thereof. Background Art

[0002] Chicken adenogastritis is a common digestive tract disease in intensive chicken farming, mainly characterized by congestion, edema, erosion and dysfunction of the glandular stomach mucosa. In the middle and late stages of the disease, the diseased chickens are extremely emaciated and die of exhaustion. With the increase in breeding density and the fluctuation of feed raw material quality, the incidence of this disease shows a significant upward trend. The pathogenic factors of adenogastritis are complex, including mycotoxin contamination, pathogenic microorganism infection, and feeding management factors, etc. In recent years, the synergistic pathogenic effect of mycotoxins and pathogenic microorganisms has been widely concerned, forming a vicious cycle of "toxin - microorganism - inflammation".

[0003] Currently, the prevention and treatment methods for broiler adenogastritis mainly include chemical drug prevention and treatment (antibiotic treatment, antifungal drugs, proton pump inhibitors, etc.), application of biological agents (single probiotic agents, enzyme preparations, toxin adsorbents, etc.), and nutritional regulation means (acidifying agents, mucosal repair agents, immune enhancers, etc.). However, the existing technologies have at least the following defects: (1) Single mechanism of action: It fails to synchronously solve the three core problems of toxin clearance, microbial balance, and mucosal repair; (2) Loss of biological activity: The gastric acid environment and feed processing cause the inactivation of probiotics and enzyme preparations; (3) Lack of synergistic effect: There is a physical or chemical antagonism between toxin adsorbents and biological agents, such as montmorillonite adsorbing probiotics and reducing their colonization efficiency. In view of the above defects, it is urgent to propose a new method for preventing and treating broiler adenogastritis to provide a reference for clinical and production practice; and feed is an essential component in broiler breeding. If the feed or its derivatives (such as premix) can be reasonably used to achieve the prevention and treatment of adenogastritis, it will effectively improve the production performance and economic benefits of chickens.

[0004] In view of this, the present invention is specifically proposed. Summary of the Invention

[0005] The first object of the present invention is to provide a premix for preventing and treating chicken adenogastritis, which is mainly used to solve the technical defects that the existing prevention and treatment methods for chicken adenogastritis cannot comprehensively solve the problems of single mechanism of action, loss of biological activity of the preparation, and lack of synergistic effect.

[0006] The second object of the present invention is to provide a preparation method of the premix for preventing and treating chicken adenogastritis.

[0007] The third object of the present invention is to provide an animal feed for preventing and treating adenogastritis.

[0008] It has been found through research that the bacteria-enzyme synergistic system has good technical prospects for preventing chicken glandular gastritis. Specifically, the bacteria-enzyme synergistic system in the present invention includes three parts: directional degradation, microecological remodeling, and mucosal repair. First, directional degradation converts the mycotoxin contamination, which is one of the pathogenic factors, into low-toxic metabolites through specific enzymes (for example, aflatoxin B1 is converted by aflatoxin-decomposing enzyme in the present invention), and directional degradation further neutralizes the toxin activity through the reduced glutathione produced by the metabolism of probiotics. Second, microecological remodeling inhibits or eliminates pathogenic bacteria through a specific combination of probiotics (for example, the exopolysaccharide secreted by Saccharomyces boulardii can inhibit the formation of Helicobacter pylori biofilm in the present invention, and its combination with Bacillus subtilis can increase the clearance rate of pathogenic bacteria by 3 times). Third, mucosal repair regenerates or repairs the glandular stomach mucosa of the chicken lesions through microorganisms (for example, γ-aminobutyric acid produced by the metabolism of Pediococcus acidilactici promotes the regeneration of the mucus layer in the present invention, and its synergism with curcumin can increase the ulcer healing rate by 50%). However, the efficient synergism of bacteria and enzymes in the bacteria-enzyme synergistic system still faces other key technical challenges, such as: the optimal pH of enzymes is usually neutral, which does not match the pH of 2.0-3.5 in the chicken gastric acid environment; the high temperature (75°C-90°C) and high shear force in feed processing are likely to cause the inactivation of bioactive components; the compatibility problem between toxin adsorbents and bacteria enzymes, and traditional adsorbents will non-specifically adsorb beneficial components, etc.

[0009] In order to achieve the above object of the present invention, the following technical solutions are specifically adopted:

[0010] A premix for preventing and treating chicken glandular gastritis, comprising: compound probiotic microcapsules, compound enzyme preparations, functional excipients, and carriers;

[0011] Among them, the functional excipients include nano-modified silicoaluminate, Jerusalem artichoke powder, curcumin microcapsules, and vitamin E succinate;

[0012] The compound probiotic microcapsules are prepared by drying a W / O / W emulsion, and the W / O / W emulsion includes an outer aqueous phase, a middle oil phase, and an inner aqueous phase, and the inner aqueous phase includes a probiotic complex.

[0013] A preparation method of the premix for preventing and treating chicken glandular gastritis as described above, comprising the following steps:

[0014] Mix the components of the middle oil phase and the inner aqueous phase, homogenize at 8000 rpm - 15000 rpm until uniform, then add the outer aqueous phase, and homogenize at 4000 rpm - 8000 rpm until uniform to obtain a W / O / W emulsion; subject the W / O / W emulsion to low-temperature spray drying to obtain compound probiotic microcapsules;

[0015] The composite probiotic microcapsules, composite enzyme preparation, functional excipients and carrier are mixed through four-stage amplification to obtain a premix precursor, and the premix precursor is hermetically activated at 30°C to 40°C to obtain a premix for preventing and treating chicken glandular gastritis.

[0016] An animal feed for preventing and treating glandular gastritis, comprising the premix for preventing and treating chicken glandular gastritis.

[0017] Compared with the prior art, the beneficial effects of the present invention are as follows: The present invention provides a premix for preventing and treating chicken glandular gastritis based on the combined action of bacteria and enzymes, and has excellent preventive and therapeutic effects on the glandular gastritis of broilers in particular; the present invention realizes the three-level technical effects of "toxin degradation - flora regulation - mucosal repair" through the spatio-temporal coordination of aflatoxin-decomposing enzyme and triple probiotics; and uses nano-modified silicate as a directional adsorption carrier, and the amino functional groups grafted on its surface can specifically bind to the carbonyl structure of aflatoxin B1; through a three-stage microencapsulation process, it is ensured that the survival rate of bacteria and enzymes in the gastric acid environment is >85%, and targeted release in the intestine. The present invention breaks through the single action mode of traditional prevention and treatment means, and provides a new solution for the prevention and control of chicken glandular gastritis through the interdisciplinary integration of materials science, microbial engineering and enzyme engineering, and has significant economic and social benefits. Detailed implementation manners

[0018] The technical solutions of the present invention will be clearly and completely described below in conjunction with the specific implementation manners. However, those skilled in the art will understand that the following described embodiments are some embodiments of the present invention, rather than all embodiments, and are only used to illustrate the present invention, and should not be construed as limiting the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative efforts fall within the scope of protection of the present invention. Those not specified in the embodiments are carried out according to the conventional conditions or the conditions recommended by the manufacturer. The reagents or instruments not specified in the manufacturer are all conventional products that can be obtained through commercial purchase. In addition, the terms "first", "second", and "third" are only used for descriptive purposes, and cannot be understood as indicating or implying relative importance.

[0019] The first aspect of the present invention lies in providing a premix for preventing and treating chicken glandular gastritis.

[0020] The premix includes the following components: composite probiotic microcapsules, composite enzyme preparation, functional excipients and carrier; wherein, the functional excipients include nano-modified silicate, Jerusalem artichoke powder, curcumin microcapsules and vitamin E succinate; the composite probiotic microcapsules are prepared by drying an W / O / W emulsion, and the W / O / W emulsion includes an outer aqueous phase, a middle oil phase and an inner aqueous phase, and the inner aqueous phase includes a probiotic complex.

[0021] As a preferred embodiment, the premix comprises the following components by mass parts: 120-180 parts of compound probiotic microcapsules, 60-100 parts of compound enzyme preparation, 250-330 parts of functional excipients, and 390-570 parts of carrier. In some alternative embodiments, the mass parts of the components of the premix include, but are not limited to: 120, 125, 130, 140, 150, 160, 170, 175, 180 parts of compound probiotic microcapsules; 60, 65, 70, 80, 90, 95, 100 parts of compound enzyme preparation; 250, 260, 270, 280, 290, 300, 310, 320, 330 parts of functional excipients; 390, 400, 425, 450, 475, 500, 525, 550, 570 parts of carrier; the above mass parts can adopt any of the listed point values, or can adopt the numerical range formed by any two point values.

[0022] As a preferred embodiment, the compound probiotic microcapsules, the compound enzyme preparation and the functional excipients are loaded in the pores or on the surface of the carrier.

[0023] As a preferred embodiment, the probiotic complex includes Bacillus subtilis, Saccharomyces boulardii and Pediococcus acidilactici; in some more preferred embodiments, the viable cell numbers in the probiotic complex (or in the compound probiotic microcapsules) include: Bacillus subtilis ≥ 5.0*10 10 CFU / g, Saccharomyces boulardii ≥ 2.0*10 10 CFU / g, Pediococcus acidilactici ≥ 1.0*10 11 CFU / g.

[0024] In the compound probiotic microcapsules, the W / O / W emulsion conforms to the well-known definition, that is, a water-in-oil-in-water (Water-in-Oil-in-Water) type emulsion, satisfying the structural characteristics of an outer continuous aqueous phase, a middle dispersed oil phase and an inner dispersed aqueous phase.

[0025] As a preferred embodiment, the outer aqueous phase includes chitosan, and the stability of the whole emulsion system is achieved through the outer aqueous phase; in some more preferred embodiments, in the outer aqueous phase, the content of chitosan is 0.08 wt.% - 0.3 wt.%, the solvent of the outer aqueous phase is an aqueous solution of acetic acid, and the concentration of the aqueous solution of acetic acid is 0.8 wt.% - 3 wt.%.

[0026] As a preferred embodiment, the intermediate oil phase includes at least one of monoglyceride, polyglycerol ester or lecithin, and one of beeswax or shellac; it should be noted that when using the shellac, a plasticizer (such as triethyl citrate) needs to be added as an auxiliary. By wrapping the inner aqueous phase with the intermediate oil phase, an encapsulating protection for the intermediate oil phase is formed, and oil droplets are formed and dispersed in the outer aqueous phase; in some more preferred embodiments, the mass ratio of the monoglyceride to the beeswax is (2-5):1.

[0027] As a preferred embodiment, the inner aqueous phase includes a probiotic complex, and also includes at least one of trehalose or mannitol, and at least one of glutamine or arginine; in some more preferred embodiments, in the inner aqueous phase, when the following components are used: the content of the trehalose is 8 wt.% - 15 wt.%, the content of the mannitol is 28 wt.% - 35 wt.%, the content of the glutamine and / or the arginine is 3 wt.% - 8 wt.%, the addition amount of the probiotic complex can be adjusted adaptively according to the bacterial activity provided above.

[0028] As a preferred embodiment, in the W / O / W emulsion, the volume ratio of the outer aqueous phase, the intermediate oil phase and the inner aqueous phase is (8-12):(3-5):1.

[0029] As a preferred embodiment, the complex enzyme preparation includes aflatoxin-decomposing enzyme, acid protease and β-glucanase, wherein the β-glucanase is of a high-temperature resistant variety and can still maintain high catalytic activity under high-temperature conditions (≥50°C).

[0030] As a more preferred embodiment, the enzyme activities of the complex enzyme preparation include: aflatoxin-decomposing enzyme ≥15000 U / g, acid protease ≥25000 U / g, β-glucanase ≥18000 U / g.

[0031] As a preferred embodiment, the functional excipients include the following components by weight: 18-25 parts of nano-modified aluminosilicate, 4-7 parts of Jerusalem artichoke powder, 2.5-4 parts of curcumin microcapsules, and 0.8-1.5 parts of vitamin E succinate. In some optional embodiments, the weight percentages of the components in the functional excipients include, but are not limited to: 18, 19, 20, 21, 22, 23, 24, and 25 parts of nano-modified aluminosilicate; 4, 4.5, 5, 5.5, 6, 6.5, and 7 parts of Jerusalem artichoke powder; 2.5, 2.75, 3, 3.25, 3.5, 3.75, and 4 parts of curcumin microcapsules; and 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, and 1.5 parts of vitamin E succinate. The above weight percentages can be any of the listed points or a numerical range formed by any two points.

[0032] It is worth noting that the weight proportions of the functional excipients and the premix components are measured independently, and the two do not adopt the same weight proportion ratio dimension; that is, those skilled in the art should not think that when the weight of the composite probiotic microcapsules is 120 to 180 parts, the weight of the nano-modified aluminosilicate is 18 to 25 parts.

[0033] As a preferred embodiment, the nano-modified aluminosilicate is obtained based on aluminosilicate after surface amino modification treatment; in the present invention, by modifying conventional aluminosilicate, its specific surface area can be significantly increased, and a sub-nanometer mesoporous structure can be formed, thereby enhancing the specific adsorption of aflatoxin by aluminosilicate; in some more preferred embodiments, the particle size of the nano-modified aluminosilicate is 80nm to 200nm.

[0034] In some optional embodiments, the preparation method of the nano-modified aluminosilicate can be as follows: aluminosilicate or a raw material with aluminosilicate as the main component (such as ZSM-5, Y-type zeolite, etc.) and a silane coupling agent (such as KH-550, APTES, AEAPTMS, etc.) are fully mixed in an organic solvent, and then separated to obtain the nano-modified aluminosilicate. As a more preferred embodiment, the preparation method of the nano-modified aluminosilicate includes: mixing the aluminosilicate with an ethanol solution of γ-aminopropyltriethoxysilane, controlling the solid-liquid ratio to 1:8-12 (g / mL), performing ultrasonic treatment, washing, and drying to obtain the nano-modified aluminosilicate.

[0035] As a preferred embodiment, the curcumin microcapsule is a preparation form in which curcumin is encapsulated in tiny vesicles through microencapsulation technology, which can effectively improve the stability, solubility, bioavailability and targeting of curcumin; the curcumin content in the curcumin microcapsule is 20 wt.% to 25 wt.%. In some more preferred embodiments, the types of capsule membranes of the curcumin microcapsules include hydrogenated palm oil, ethyl cellulose, gum arabic or gelatin, etc., but hydrogenated palm oil is further preferably used as the capsule skin material.

[0036] As a preferred embodiment, the carrier includes at least one of defatted rice bran, wheat bran or corncob powder; the particle size of the carrier is 60 mesh to 100 mesh, the porosity of the carrier is 50% to 65%, and the specific surface area of the carrier is 3 m 2 / g to 5 m 2 / g.

[0037] The second aspect of the present invention is to provide a preparation method of the premix for preventing and treating chicken glandular gastritis as described in the first aspect. The preparation method includes the following steps:

[0038] (1) Mix the components of the intermediate oil phase and the inner aqueous phase, homogenize at 8000 rpm to 15000 rpm until uniform, then add the outer aqueous phase, and homogenize at 4000 rpm to 8000 rpm until uniform to obtain a W / O / W emulsion; subject the W / O / W emulsion to low-temperature spray drying to obtain composite probiotic microcapsules.

[0039] (2) Obtain a premix precursor by mixing the composite probiotic microcapsules, the composite enzyme preparation, the functional excipient and the carrier through four-stage amplification mixing, and seal and activate the premix precursor at 30°C to 40°C to obtain a premix for preventing and treating chicken glandular gastritis.

[0040] As a preferred embodiment, the inlet air temperature of the low-temperature spray drying is 40°C to 60°C, the outlet air temperature of the low-temperature spray drying is 20°C to 30°C, and the atomization pressure of the low-temperature spray drying is 0.7 MPa to 0.85 MPa.

[0041] As a preferred embodiment, pretreatment of the carrier is further included before the preparation method, including the following steps: fully mix the carrier with oil to reduce the dust of the carrier; in some more preferred embodiments, the oil includes but is not limited to soybean oil, corn oil, sunflower oil, wheat germ oil, etc.; in some more preferred embodiments, the mass ratio of the oil to the carrier is 0.5% to 3%.

[0042] As a preferred embodiment, the four-stage amplification mixing includes the following steps: S1, fully mixing the nano-modified aluminosilicate, Jerusalem artichoke powder and the carrier; S2, fully mixing the mixture of S1 with the complex enzyme preparation; S3, fully mixing the mixture of S2, the complex probiotic microcapsules and the curcumin microcapsules; S4, spraying vitamin E succinate into the mixture of S3.

[0043] As a preferred embodiment, the relative humidity of the activation environment is 80% to 90%.

[0044] As a preferred embodiment, the activation time is 10 hours to 15 hours.

[0045] A third aspect of the present invention provides an animal feed for preventing and treating proventriculus, comprising the premix for preventing and treating proventriculus in chickens described in the first aspect. It is understood that the animal feed should also include nutrients to meet the specific needs of animal growth, production, and life maintenance, including but not limited to energy feed, protein feed, roughage, etc. The present invention does not impose any restrictions on the specific ingredients of the animal feed. In some preferred embodiments, the mass ratio of the premix to the feed is 1.2% to 1.5%.

[0046] Example 1

[0047] (1) Preparation of nano-modified hydrated aluminosilicate:

[0048] The hydrated aluminosilicate was immersed in a 3 wt.% APTES (γ-aminopropyltriethoxysilane) ethanol solution with a solid-liquid ratio of 1:10 (g / mL); ultrasonically treated at 60°C for 2 hours, then centrifuged and washed until neutral, and dried at 120°C to obtain nano-modified hydrated aluminosilicate.

[0049] (2) Preparation of composite probiotic microcapsules:

[0050] (2-1) Preparation of W / O / W emulsion: Preparation of probiotic compound (including: Bacillus subtilis 6.0*10 10 CFU / g, Saccharomyces boulardii 2.5*10 10 CFU / g, Pediococcus acidilactici 2.0*10 11 CFU / g), take 200g / L of probiotic complex, add 10wt.% trehalose and 5wt.% glutamine to it to obtain the inner aqueous phase; prepare monoglyceride and beeswax (mass ratio is 3:1), melt them and cool to 45℃ to obtain the oil phase; prepare 1wt.% acetic acid aqueous solution, add 0.1wt.% chitosan to obtain the outer aqueous phase;

[0051] During primary emulsification, first mix the inner aqueous phase and the oil phase at a volume ratio of 1:4 and homogenize at 10,000 rpm for 3 min; during secondary emulsification, mix the primary emulsion and the outer aqueous phase at a volume ratio of 1:2 and homogenize at 6,000 rpm for 2 min.

[0052] (2-2) Low-temperature spray drying: Place the homogenized emulsion in a spray drying device, set the inlet air temperature at 45 °C, the outlet air temperature at 28 °C, and the atomization pressure at 0.8 MPa.

[0053] (3) Raw material preparation:

[0054] Compound enzyme preparation: Aflatoxin-decomposing enzyme 16,000 U / g, acid protease 25,000 U / g, heat-resistant β-glucanase 18,500 U / g;

[0055] Functional excipients: Nano-modified hydrated silicoaluminate 200 g, Jerusalem artichoke powder 50 g, curcumin microcapsule 30 g, vitamin E succinate 10 g;

[0056] Compound probiotic microcapsule 150 g, compound enzyme preparation 90 g, total functional excipients 290 g, carrier defatted rice bran (80 mesh) 470 g.

[0057] (4) Preparation of premix:

[0058] (4-1) Carrier pretreatment: Premix defatted rice bran passed through an 80-mesh sieve with 1 wt.% soybean oil.

[0059] (4-2) Gradual amplification mixing: First mix the nano-modified hydrated silicoaluminate and Jerusalem artichoke powder evenly; then add the compound enzyme preparation and mix evenly; then add the compound probiotic microcapsule and curcumin microcapsule and mix evenly; finally, spray and add vitamin E succinate.

[0060] (4-3) Solid-state activation: Treat the mixture obtained in the previous step in a closed environment at 35 °C and a relative humidity of 85% for 12 h to obtain the premix of this example.

[0061] Example 2

[0062] It is basically the same as Example 1, with the only difference being that in step (3), some characteristics are replaced with: compound probiotic microcapsule 180 g, compound enzyme preparation 60 g, total functional excipients 290 g, carrier defatted rice bran 470 g.

[0063] Example 3

[0064] It is basically the same as Example 1, with the only difference being that in step (3), some characteristics are replaced with: compound probiotic microcapsule 120 g, compound enzyme preparation 100 g, total functional excipients 290 g, carrier defatted rice bran 490 g.

[0065] Example 4

[0066] It is basically the same as Example 1, except that in step (3), some features are replaced with: The functional excipients include: 190 g of nano-modified hydrated aluminosilicate, 60 g of Jerusalem artichoke powder, 28 g of curcumin microcapsules, and 12 g of vitamin E succinate.

[0067] Example 5

[0068] It is basically the same as Example 1, except that in step (4-3), some features are replaced with: Treat in a sealed environment at 40 °C and a relative humidity of 88% for 11 h.

[0069] Comparative Example 1

[0070] It is basically the same as Example 1, except that step (1) is cancelled and conventional hydrated aluminosilicate is used to replace nano-modified aluminosilicate.

[0071] Comparative Example 2

[0072] It is basically the same as Example 1, except that the addition of Jerusalem artichoke powder is cancelled and the mass ratio of the functional excipients is replaced with: 240 g of nano-modified hydrated aluminosilicate, 38 g of curcumin microcapsules, and 12 g of vitamin E succinate.

[0073] Comparative Example 3

[0074] It is basically the same as Example 1, except that the addition of curcumin microcapsules is cancelled and the mass ratio of the functional excipients is replaced with: 220 g of nano-modified hydrated aluminosilicate, 58 g of Jerusalem artichoke powder, and 12 g of vitamin E succinate.

[0075] Comparative Example 4

[0076] It is basically the same as Example 1, except that the addition of vitamin E succinate is cancelled and the mass ratio of the functional excipients is replaced with: 208 g of nano-modified hydrated aluminosilicate, 51 g of Jerusalem artichoke powder, and 31 g of curcumin microcapsules.

[0077] Comparative Example 5

[0078] It is basically the same as Example 1, except that step (2) is cancelled and the probiotic complex in (2-1) is used to replace the composite probiotic microcapsules.

[0079] Test Example

[0080] The therapeutic effects of the premixes in each example and comparative example were evaluated through animal experiments. 300 one-day-old AA broilers were selected for the experiment. In addition, a negative control group, a positive control group, an antibiotic treatment group, and a traditional probiotic treatment group were set up, with 5 replicates in each group and 12 chickens in each replicate, with an equal number of males and females.

[0081] Among them, the negative control group did not undergo the modeling of glandular gastritis; the positive control group underwent the modeling of glandular gastritis but did not adopt any treatment means; the antibiotic treatment group added 0.2 wt.% enrofloxacin to the complete feed; the traditional probiotic treatment group added 0.5 wt.% of a conventional composite bacteria (Bacillus subtilis + Lactobacillus acidophilus + Saccharomyces cerevisiae, with a mass ratio of 1:1:1 for the three) to the complete feed. Each example and comparative example were added to the complete feed at 1.2 wt.% and the corresponding premix treatment groups for each example and comparative example were prepared.

[0082] The complete feed used in this test example included the following components by weight percentage: 60% corn, 30.4% soybean meal, 3% corn protein powder, 2% soybean oil, 1.2% stone powder, 1.8% calcium hydrogen phosphate, 0.36% salt, 0.12% methionine, 0.12% lysine, and 1% multivitamin and multimineral premix.

[0083] Except for the negative control group, each treatment group was intragastrically administered a suspension containing AFB1 (200 μg / kg) and avian adenovirus (105 TCID50) continuously for 3 days starting from the 7th day of age to form the glandular gastritis model; the modeling situation was evaluated on the 10th day of age, and then the treatment diets of each group were started to be fed, and the feeding continued for 5 days. The growth performance of each group was statistically analyzed on the 15th day of age, and samples were taken by dissection and relevant indicators were detected.

[0084] On the 10th day of age, 2 chickens were selected from each replicate of each group for dissection to observe the lesions of the glandular stomach. Serum and glandular stomach mucosa were taken to detect inflammatory factors, and the results were recorded in Table 1. The results showed that the broilers in the negative control group had normal behavior and normal glandular stomach morphology; while the broilers in other groups had a decrease in feed intake and more serious glandular stomach swelling, manifested as white patches on the surface of the glandular stomach, isthmus edema, and the levels of mucosal TNF-α and serum IL-6 were significantly higher than those in the negative control group.

[0085] Table 1

[0086] Mucosal TNF-α (ng / mg) Serum IL-6 (pg / mL) Negative control group 0.33±0.05 16.22±1.69 Positive control group 3.61±0.33 69.26±3.64 Antibiotic prevention and treatment group 3.84±0.16 58.43±5.88 Traditional probiotic prevention and treatment group 3.69±0.24 61.75±8.23 Example / Comparative example prevention and treatment group 3.87±0.29 64.64±4.59

[0087] On the 15th day of age, the clinical manifestations of the broilers in each group were observed, the growth performance was statistically analyzed, 2 chickens were selected from each replicate of each group for dissection to observe the lesions of the glandular stomach, serum and glandular stomach mucosa were taken to detect inflammatory factors, and the residual amount of aflatoxin B1 in the glandular stomach was detected, and the results were recorded in Table 2.

[0088] Table 2

[0089]

[0090]

[0091] The results showed that the broilers in the positive control group continuously showed a decrease in feed intake and reduced activity. The feed intake in the treatment groups with proportioned premixes, antibiotic treatment group, and traditional probiotic treatment group rebounded to some extent. The feed intake in the premix treatment groups of each example rebounded to a greater extent. The average weight of the premix treatment group at 15 days of age was already close to that of the negative control group.

[0092] Upon autopsy, it was found that the glandular stomach lesions in the premix treatment groups corresponding to each example improved significantly. The levels of TNF-α in the glandular stomach mucosa and IL-6 in the serum decreased significantly. The residual amount of AFB1 in the glandular stomach was also significantly lower than that in the positive control group, antibiotic treatment group, traditional probiotic treatment group, and the treatment group with proportioned premixes of the comparative example. The above results indicate that a premix for preventing and treating broiler glandular gastritis based on the combined action of bacteria and enzymes prepared according to the present invention has excellent treatment effects on broiler glandular gastritis.

[0093] Although the present invention has been illustrated and described with specific examples, it should be realized that the above examples are only used to illustrate the technical solutions of the present invention, rather than limiting it; those of ordinary skill in the art should understand that: without departing from the spirit and scope of the present invention, the technical solutions described in the foregoing examples can be modified, or some or all of the technical features can be equivalently replaced; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention; therefore, this means that all such replacements and modifications within the scope of the present invention are included in the appended claims.

Claims

1. A premix for preventing and treating chicken glandular gastritis, characterized in that, The premix comprises: composite probiotic microcapsules, composite enzyme preparations, functional excipients and carriers; The functional excipients include nano-modified aluminosilicate, Jerusalem artichoke powder, curcumin microcapsules and vitamin E succinate; The composite probiotic microcapsule is prepared by drying a W / O / W emulsion, wherein the W / O / W emulsion comprises an outer water phase, an intermediate oil phase and an inner water phase, and the inner water phase comprises a probiotic compound.

2. The premix according to claim 1, characterized in that, The premix comprises the following components by mass: 120-180 parts of composite probiotic microcapsules, 60-100 parts of composite enzyme preparations, 250-330 parts of functional excipients, and 390-570 parts of carriers; And / or, the functional excipients include the following components in parts by weight: 18-25 parts of nano-modified aluminosilicate, 4-7 parts of Jerusalem artichoke powder, 2.5-4 parts of curcumin microcapsules and 0.8-1.5 parts of vitamin E succinate.

3. The premix according to claim 1, characterized in that, The probiotic compound comprises Bacillus subtilis, Saccharomyces boulardii and Pediococcus acidilactici; Preferably, the viable count of the compound probiotic microcapsules includes: Bacillus subtilis ≥ 5.0×10 10 CFU / g, Saccharomyces boulardii ≥ 2.0×10 10 CFU / g, Pediococcus acidilactici ≥ 1.0×10 11 CFU / g.

4. The premix according to claim 1, wherein The complex enzyme preparation comprises aflatoxin decomposing enzyme, acid protease and β-glucanase; Preferably, the enzyme activities of the complex enzyme preparation include: aflatoxin decomposing enzyme ≥ 15000 U / g, acid protease ≥ 25000 U / g, and β-glucanase ≥ 18000 U / g.

5. The premix according to claim 1, characterized in that, The nano-modified aluminosilicate is obtained by surface modification of aluminosilicate by amino treatment; Preferably, the particle size of the nano-modified aluminosilicate is 80 nm to 200 nm.

6. The premix according to claim 1, characterized in that, The premix satisfies at least one of the following characteristics (a) to (d): (a) the volume ratio of the outer aqueous phase, the middle oil phase and the inner aqueous phase is (8-12):(3-5):1; (b) the outer aqueous phase comprises an aqueous solution of chitosan and acetic acid, and the content of the chitosan is 0.08 wt.% to 0.3 wt.%; (c) the intermediate oil phase comprises at least one of monoglyceride, polyglyceride or lecithin; the intermediate oil phase further comprises one of beeswax or shellac; (d) The inner aqueous phase further comprises at least one of trehalose or mannitol; and the inner aqueous phase further comprises at least one of glutamine or arginine.

7. The preparation method of the premix for preventing and treating chicken glandular gastritis according to any one of claims 1 to 6, characterized in that, The steps include: The components of the intermediate oil phase and the inner aqueous phase are mixed and homogenized at 8000 rpm to 15000 rpm until uniform, and then the outer aqueous phase is added and homogenized at 4000 rpm to 8000 rpm until uniform to obtain a W / O / W emulsion; the W / O / W emulsion is spray-dried at low temperature to obtain composite probiotic microcapsules; The composite probiotic microcapsules, composite enzyme preparations, functional auxiliary materials and carriers are mixed through four-stage amplification to obtain a premix precursor, and the premix precursor is sealed and activated at 30-40° C. to obtain a premix for preventing and treating chicken glandular gastritis.

8. The preparation method according to claim 7, wherein The air inlet temperature of the low-temperature spray drying is 40° C. to 60° C., the air outlet temperature of the low-temperature spray drying is 20° C. to 30° C., and the atomization pressure of the low-temperature spray drying is 0.7 MPa to 0.85 MPa.

9. The preparation method according to claim 7, characterized in that, The four-stage amplification mixing comprises the following steps: S1. Thoroughly mix the nano-modified silicoaluminate, Jerusalem artichoke powder and the carrier; S2. Thoroughly mix the mixture of S1 with the composite enzyme preparation; S3. Thoroughly mix the mixture of S2, the composite probiotic microcapsule and the curcumin microcapsule; S4. Spray vitamin E succinate into the mixture of S3.

10. An animal feed for preventing and treating glandular gastritis, characterized in that, It includes a premix for preventing and treating chicken gizzard gastritis as described in any one of claims 1 to 6.

Images